Balaxi Pharmaceuticals Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported sales was INR 865.82 million compared to INR 617.24 million a year ago. Revenue was INR 820.17 million compared to INR 613.23 million a year ago. Net income was INR 82.29 million compared to INR 121.8 million a year ago. Basic earnings per share from continuing operations was INR 8.21 compared to INR 12.18 a year ago. Diluted earnings per share from continuing operations was INR 8.03 compared to INR 12.18 a year ago.
For the nine months, sales was INR 2,557.51 million compared to INR 1,902.89 million a year ago. Revenue was INR 2,586.09 million compared to INR 1,911.94 million a year ago. Net income was INR 378.62 million compared to INR 349.47 million a year ago. Basic earnings per share from continuing operations was INR 37.83 compared to INR 34.95 a year ago. Diluted earnings per share from continuing operations was INR 37.55 compared to INR 34.95 a year ago.